Pricing is expected within 1-2 days. The lack of a minimum closing amount means actual proceeds could be far below $7M, and the massive dilution (~237%) will pressure the stock. Monitor for the 424B pricing filing and any subsequent Nasdaq compliance update.
Price Chart
Executive Summary
The SEC declared effective Sunshine Biopharma's S-1 registration (File No. 333-299274) on October 7, 2026, enabling the company to proceed with a best-efforts offering of up to 10,180,337 Common Units at an assumed price of $0.6876 per unit, targeting up to $7.0 million in gross proceeds. The offering is highly dilutive — pro forma shares would increase from 4.3M to 14.5M — and has no minimum closing amount, creating significant uncertainty about actual proceeds. This effectiveness removes the final regulatory hurdle, and pricing is expected imminently.
Key Facts
- EFFECT notice for S-1 registration statement File No. 333-299274, declared effective October 7, 2026.
- Offering consists of up to 10,180,337 Common Units (each: one share of common stock + two Series D Warrants) at an assumed price of $0.6876 per unit.
- Maximum gross proceeds targeted: $7.0 million.
- No minimum closing amount — actual proceeds may be substantially less than the maximum.
- Pro forma shares outstanding would increase from 4.3M to approximately 14.5M, representing ~237% dilution.
- Company had only $13.7M in cash as of June 30, 2026, and faces Nasdaq minimum bid price non-compliance.
- The S-1 was filed on October 2, 2026, and the EFFECT was issued 5 days later.
Financial Impact
Up to $7.0 million in gross proceeds from a highly dilutive offering; pro forma share count increases ~237% from 4.3M to 14.5M shares.
Risk Factors
- Extreme dilution of ~237% from the offering, severely diluting existing shareholders.
- No minimum offering amount — the company may raise far less than the $7M maximum, leaving it undercapitalized.
- Nasdaq minimum bid price non-compliance risk persists, potentially leading to delisting.
- Best-efforts structure means the placement agent (Aegis Capital) is not obligated to purchase any unsold units.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003179 |
| Document: 9999999995-26-003179-index.html | 9999999995-26-003179 |
| Document: 9999999995-26-003179.txt | 9999999995-26-003179 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $3.19 (+1212.72%) |
Oct 13, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $3.19 (+1212.72%) |
Oct 9, 2026 17d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $3.19 (−956.26%) |
Oct 9, 2026 17d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $3.19 (−956.26%) |
Oct 8, 2026 19d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | $3.19 (−641.84%) |
Oct 5, 2026 21d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | $3.19 (−701.68%) |
Oct 2, 2026 24d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | $3.19 (−659.32%) |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | $3.19 (−184.81%) |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | $3.19 (+184.81%) |
Aug 3, 2026 12w ago | 8-K | $23.40 $24.40 | ▲ +4.27% | ▲ +2.25% | $3.19 (−86.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers